Committed to serving patients with muscular dystrophy
Muscular Dystrophy (MD) is a devastating genetic disease affecting children and adults and is characterized
by mild to severe muscle weakness. Many forms of muscular dystrophy exhibit a progressive disease course that
often leads to loss of ambulation, loss of independence, poor quality of life and decreased lifespan.
The Muscular Dystrophies represents one of the largest orphan disease indications in the world. Most forms of the muscular dystrophies have no effective treatments, representing a large unmet need.
Prothelia is a Massachusetts based biopharmaceutical corporation focused on bringing therapeutics to patients suffering from muscular dystrophy. Our vision includes:
- Extending and improving the quality of life for affected individuals
- Working with leading academic institutions to identify and develop therapeutics
- Leveraging deep relationships with other pharmaceutical corporations and advocacy groups to speed product development and reduce product risk
- Partnering with regulatory agencies and clinicians to approve and run clinical trials
- Efficiently executing our business model to reduce investor risk and increase shareholder value
